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dominated by gut epithelial proteinsTo the Editor:
Regulatory T (Treg) cells play a key role in immune system
homeostasis by suppressing detrimental immune responses
against self-proteins, in particular in the intestine.1 Patients with
mutations in the gene FOXP3 display a severe defect of Treg-
cell function that results in IPEX syndrome (OMIM 304790)
characterized by impaired immune tolerance and multiorgan
autoimmunity. Dermatitis, type 1 diabetes, and in particular auto-
immune enteropathy are hallmarks of the syndrome. Intestinal
Treg cells normally suppress immune responses against harmless
dietary antigens and commensal microorganisms, but the intesti-
nal self-proteins that are guarded by Treg cells have not yet been
fully identified.2
Patients with IPEX and enteritis typically harbor autoanti-
bodies against harmonin (USH1C) and villin, which are structural
proteins predominantly expressed in brush border epithelia of the
intestine and renal tubules.3,4 Autoantibodies against glutamate
decarboxylase-65 (GAD-65, GAD2),5 which is a marker for islet
cell autoimmunity in type 1 diabetes, have been detected in pa-
tients with IPEX already in their first week of life. These studies
suggest that the autoimmune pathogenesis of IPEX involves a hu-
moral response that can be exploited for identifying the immune
targets.6 Hitherto, no studies have been undertaken to characterize
autoantigens in IPEX syndrome in a comprehensive way. Here,
we sought to identify the autoantibody targets in patients with
IPEX on a broad scale to gain better understanding of the autoim-
mune manifestations of IPEX and insights to peripheral tolerance
mechanisms mediated by Treg cells.
We used panels of more than 9000 human proteins to
characterize autoantibody targets in 14 patients with IPEX and
24 healthy controls (detailed methodology and additional tables/
figures are available in this article’s Online Repository at www.
jacionline.org). In total 20 proteins clearly stood out as patient-
specific autoantigens (Fig 1; see Table E1 in this article’s Online 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Repository at www.jacionline.org). Among them, the 3 previ-
ously known IPEX autoantigens included in the panels were all
present: harmonin,3 a-IFN,7 and GAD-65,5 verifying a reliable
detection of autoantibodies (Fig 1, C, and Fig E1).
Interestingly, the new autoantigens showed predominant
expression in tissues typically affected in patients with IPEX, in
particular in the intestinal epithelium. In the brush border of
enterocytes, ANKS4B and harmonin form a complex that anchors
transmembrane links reaching between the tips of microvilli to
the enterocyte cytoskeleton (Fig 2, A). Competition assays re-
vealed no autoantibody cross-reactivity, suggesting that harmonin
and ANKS4B were independent autoantigens (see Fig E2 in this
article’s Online Repository at www.jacionline.org). Another
novel autoantigen, ACSL5, is primarily expressed in the small in-
testine, where it regulates the enterocyte proliferation along the
crypt-villus axis. The protein with the strongest autoantibody
signal in the protein array data, HNF4A, is a nuclear receptor
with an expression pattern that closely follows that of harmonin
and ANKS4B. HNF4A has important functions in differentiation
of intestinal and renal epithelia. To validate the proteome-wide
autoantibody data with an independent method, we developed
radio-ligand binding assays for a subset of the new candidate
autoantigens ANKS4B, HNF4A, PPARG, and RXRA, as well
as for 3 established autoantigens: GAD-65, harmonin, and villin.
We extended the group of patients with IPEXwith 3 additional pa-
tients in the validation experiments (n 5 17). To better evaluate
the clinical specificity, we also included a larger group of healthy
subjects (n5 75) and sera from other autoimmune and inflamma-
tory diseases: inflammatory bowel disease (n5 20), autoimmune
polyendocrine syndrome (APS) type 1 (n 5 20), and APS-2
(n 5 40). The novel autoantigens ANKS4B, HNF4A, PPARG,
and RXRAwere all confirmed in the radio-ligand binding assay
and showed high specificity for IPEX in the investigated clinical
material (see Figs E3 and E4 in this article’s Online Repository at
www.jacionline.org).
Among the 16 patients with IPEX and enteropathy, 11 of 16
(69%) were positive for autoantibodies against harmonin, 9 of
16 (56%) against ANKS4B, 7 of 16 (44%) against HFN4A, and 8
of 14 (57%) against ACSL5 (ACSL5 autoantibody data were
available only for the discovery case group) (Fig 2,B). Hence, 11
of 16 patients (69%) displayed autoantibodies against 1 or more
autoantigens in the intestinal epithelium. Although the number
of patients without enteropathy was too small to assess any sta-
tistical associations with specific autoantibodies, we noted that
the only patient without enteropathy was negative for all the in-
testinal autoantibodies. Two patients were negative for all inves-
tigated autoantibodies. Both these patients displayed clinical
manifestations and mutations in FOXP3 typical for IPEX
(Table E1).
Besides HNF4A, our list of top 20 targets from the protein array
contained 10 additional nuclear receptors, all with highly
correlated results. Because nuclear receptors share an evolu-
tionary template featuring a highly conserved DNA-binding
domain and a moderately conserved ligand-binding domain, we
performed competition assays to test for cross-reactivity.
Focusing on a subset of the nuclear receptor autoantigens,
HNF4A, RXRA, and PPARG, we could demonstrate a cross-
reactivity between these autoantigens (see Fig E5 in this article’s
Online Repository at www.jacionline.org). Hence, the nuclear re-
ceptor autoantibodies were specific for a subset of nuclear recep-
tors, but cross-reactive within this subset. Investigations of
FIG 1. Identification of autoantigens in IPEX by proteome-wide screen. A and B, To identify IPEX-specific
autoantigen signals, the difference in signal intensity between the second to strongest case and the
strongest healthy control was calculated for each protein target. A total of 20 protein targets stood out
from the background level, delineated by the red line, andwere selected for further scrutiny. C, The heatmap
shows the signal intensities for cases and controls, for the top 20 protein targets.
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nuclear receptor autoantibodies targeted a shared epitope in the
ligand-binding domain.
IPEX can rapidly become fatal if not aggressively treated.
Although immunosuppressive therapy can give transient or
partial improvement of disease symptoms, allogenic hematopoi-
etic stem cell transplantation (HSCT) offers the only possibility of
cure. By investigating consecutive samples from patients with
IPEX taken before and after treatment, we found that autoanti-
bodies remained detectable following immunosuppressive treat-
ment with rapamycin but completely disappeared 1.5 years
following successful HSCT (see Fig E6 in this article’s Online Re-
pository at www.jacionline.org). The replenishment of stem cells
with normal functioning FOXP3 might explain disease suppres-
sion and disappearance of autoantibodies following HSCT not
observed with immunosuppressive treatments.
Although this is by far the most comprehensive study of
autoantibody targets in IPEX, less than half of the protein coding
genes were covered in our screen. For instance, the previously
identified skin autoantigen in IPEX, keratin 14,8 was not present
in the investigated panel.In summary, we have identified intestinal self-antigens that are
implicated in the enteropathy of IPEX, which may advance the
understanding of FOXP3-dependent Treg cells in controlling
immune tolerance toward self-antigens in the gut.
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FIG 2. Enterocyte autoantigens in patients with IPEX. A, The intestinal epithelium microvilli are intercon-
nected with cadherin tip-links. The previously established autoantigen harmonin and the hereby identified
autoantigen ANKS4B are integral parts of a larger complex connecting the transmembrane tip-links to the
actin bundles of the cytoskeleton. The interacting domains of harmonin and ANKS4B are highlighted in
blue. The established autoantigen villin bundles actin filaments in the intestinal microvilli. B, Patients
with IPEX and enteritis react with enterocyte autoantigens: Harmonin, villin, ANKS4B, HNF4A, and
ACSL5. C, IPEX autoantigens show similar profiles of tissue expression. RNA-seq data were obtained
from the genotype-tissue expression (GTEx) project. NA, Not applicable/available.
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the hairless skin microbiomeTo the Editor:
Mast cells (MCs) are abundant in skin that interfaces with the
outside environment. MC precursors migrate to the skin during
embryogenesis, and they develop under the influence of tissue-
specific factors.1 Although they have a well-established MC role
in allergy, their relationship with hair is less understood. In fact,
MCs are present in lesions of patients with alopecia areata,2 and
patients with alopecia areata frequently report itching during
the activity phase of the disease. Interestingly, MC hyperplasia
is a striking feature of hairless mice discovered by Fujii et al.3
However, the mechanisms of this MC hyperplasia in hairless
mice were not investigated further. Genetically, hairless mice
are characterized by the absence of the hairless gene (Hr).
Hr is highly expressed in both human and mouse skin. Degrad-
ing HrmRNA results in transformation from hairy skin into hair-
less skin. However, MC hyperplasia observed in the skin of
hairless mice is not a distinctive feature of Hr mutant mice. In
fact, an increased number of MCs in the skin was reported in
different strains of hairless mice, including BALB/c nude mice,
a strain of mice with the absence of thymus but a normal Hr
gene.4 Moreover, a previous study noted that MC numbersincreased during the period when hair regeneration enters late an-
agen, suggesting that MC numbers can oscillate with environ-
mental changes during the hair growth cycle.5
One main characteristic of absent hair is thought to be the
physical feature of habitats for a distinctive microbiome on the
skin surface. Our group recently demonstrated that the micro-
biome induces MCmaturation in the skin because it induces stem
cell factor (SCF) production in keratinocytes, which is essential
forMC survival.6,7 Thereforewe hypothesized that changes in the
skin microbiome caused by hair loss could be an important factor
in increasing the number of MCs present in the skin of hairless
mice.
We first generated C57 HR (C57BL/6J hairless) mice, which
present with MC hyperplasia and hairless skin compared with the
hairy skin of C57 wild-type (WT) mice. We evaluated the number
of MCs in the skin and found a significant increase in MC
numbers by counting MCs from 5 tissue sections of 4 mice per
group. The average number of MCs in the C57 WT group was
246 4/mm2, whereas that in C57HRmicewas 836 16/mm2 (Fig
1, A-C). Interestingly, C57 HR newborn mice have normal first
fur, but pups start losing hair from the 14th day after birth.
Therefore, to determine whether the discontinued hair cycle
affects MCs, we verified MC numbers in hairy skin from 1-week-
old (1WO) C57 HR mice by means of avidin staining. As
expected, we found that the average number of MCs in the 1WO
C57 HR group was 51 6 3 MCs/mm2, which was less than the
average 85 6 7 MCs/mm2 in adult skin of C57 HR mice (Fig 1,
D-F, and see Fig E1 in this article’s Online Repository at www.
jacionline.org). When we compared 1WO C57 WT mice with
8-week-old mice, they had slightly fewer MCs. However, 1-
week-old C57 mice WTalready had a significantly lower number
of MCs when compared with the 1WOC57 HRmice. This differ-
ence could be considered the genetic component of HR mice for
MC numbers.
To assess the function of MCs in C57 HR mice, we examined
MC-specific enzyme activities, such as chymase and tryptase.
Immunofluorescent staining showed that there was an increased
expression of chymase in C57 HR mice that correlated with the
accumulation of excessive MCs in their dermis (Fig 1, G-J).
A remarkably high b2-tryptase (Tpsb2) expression was found in
the skin of C57 HR but not C57 WT mice (Fig 1, K). Likewise,
a strikingly high expression of trypsin-like activity was found
when we performed fluorometric analysis (Fig 1, L). In addition,
we evaluated MC function by measuring the diameter increase in
skin edema using Compound 48/80 (Sigma, St Louis, Mo). We
found that C57 HR mice had a much bigger edema area than
C57 WT mice, which indicated increased release of MC media-
tors (Fig 1, M).
We also measured MC reactivity using passive cutaneous
anaphylaxis. A larger edema area was observed in C57 HR mice,
suggesting MCs were activated by IgE (Fig 1, N). These results
demonstrate that MCs in skin of C57 HR mice are functioning
normally.
Given that our laboratory previously demonstrated that MC
maturation and migration can be promoted by using skin
commensal gram-positive bacteria through the Toll-like receptor
2 (TLR2)–SCF pathway in keratinocytes,6,7 we investigated the
composition of the skin microbiome in C57 HR and C57 WT
mice. Skin microbiome composition was assessed by using 16S
rRNA sequencing performed on 14 samples, including 8 C57
WT mice, 4 C57 HR mice, and two 1-week-old C57 HR mice.
METHODS
Clinical subjects
Patients with IPEX were included from Italy, the Unites States, and
Germany. All patients fulfilled clinical diagnostic criteria for IPEX, requiring
a disruptive FOXP3 mutation and manifestation of enteropathy and/or endo-
crinopathies. Blood donors not known to suffer from autoimmune disease
were included as healthy controls, both in the discovery (n 5 24) and in the
validation control (n 5 75) groups. The validation control groups also
included additional subjects with autoimmune diseases: 20 subjects with auto-
immune polyendocrine syndrome type 1 (APS1); 20 subjects with APS2 with
type 1 diabetes; 20 subjects with APS2 without type 1 diabetes; 10 subjects
with ulcerative colitis; and 10 subjects with Crohn disease.
Protein array screening
Protein arrays containing more than 9000 full-length human proteins
(ProtoArray v5.1, PAH05251020, ThermoFisher, Waltham, Mass) were used
to study autoantibodies in serum samples diluted 1:2000. The arrays were
probed according to the manufacturer’s protocol using the recommended
reagents: (PA055, ThermoFisher), Alexa Fluor 647 goat antihuman IgG
(A21445, ThermoFisher), Dylight 550 goat anti-GST (#DY550011-13-001,
Cayman Chemicals, Ann Arbor, Mich), and the LuxScan HT24 (BioCapital)
micro-array scanner.
Radio-ligand binding assay
Autoantibodies were measured by immunoprecipitation of antigens radio-
labeled with 35S-methionine. Complementary DNA clones were purchased
from Origene and subcloned into pTNT or Sp64 expression vectors (L5610,
Promega, Madison, Wis), which were used for transcription and translation
in vitro (Promega TNT Systems): USH1C SC336653 (NM_001297764),
ANKS4B SC306281 (NM_145865), HNF4A SC307232 (NM_178849),
PPARG SC322218 (NM_138712), RXRA SC118299 (NM_002957), VIL1
SC123608 (BC_017303). Immunoprecipitation was conducted in 96-well
filtration plates (Millipore, Burlington, Mass). Serum samples (2.5 mL)
were incubated overnight at 48Cwith 30’000 cpm of radiolabeled protein. Im-
mune complexes were captured with protein A Sepharose (Protein
A Sepharose 4 Fast Flow, GE Healthcare, Chicago, Ill) during a 45-minute in-
cubation. After 10 washing steps, radioactive decay was measured in a beta
counter (1450 Microbeta Triplex, Wallac). All serum samples were tested in
duplicate in separate wells. BSA (4%) was included in each plate to serve
as a negative standard. For each antigen, a selected IPEX or APS1 patient
serum was included in all 96-well plates to serve as a positive standard for in-
dex calculation. Autoantibody indices were calculated according to the
following: (sample value 2 negative standard value) O (positive standard
value2 negative standard value)3 100. The upper limits of the normal range
were defined as an index value of 5 SDs above the mean of the healthy
controls.
Statistics
Quantile normalization was applied to reduce the effects of technical
variation between different protein array experiments.E1 Protein targets
affected by printing contaminations were identified using a previously
described approach and removed (n 5 4).E2 Protein targets were sorted by
their difference between cases and controls. For each protein, the strongest
signal intensity in the control group was subtracted from the second to
strongest patient signal intensity. Thereby, targets with elevated signal in 2
or more patients could be selected. Clusters of autoantigens were identified
by correlation.
Study approval
All study subjects gave their informed consent for participation in
accordance with their local institutional review boards (IRBs). The study
was performed in accordance with the Declaration of Helsinki and
approved by the local ethics committees (2008/296-31/2 and 2016/2553-
31/2 by Stockholm, UP 00-052 by Uppsala, IRB protocol TIGET02 and
TIGET06 by Ospedale San Raffaele, and IRB protocol 34131 by Stanford
University).
Protein annotation
The STRING database was used for functional enrichment analysis of
PFAMprotein domains, andGO-terms describing biological processes.E3 Pro-
tein primary structures retrieved from the array manufacturer were aligned
with Clustal omega.E4,E5 Mutations were annotated using the gene transcript
hg19_knownGene_uc004dnf.4, chrX:49106897-49121288.
Protein expression levels and
immunohistochemistry
RNA-Seq data from the GTEx database were used to investigate protein
expression.E6-E8 To detail the tissue distribution of novel autoantigens, we
investigated immunohistochemical stainings retrieved from the Human Pro-
tein Atlas.E9,E10
We thank the Autoimmunity Profiling National Facility in Stockholm,
Science for Life Laboratory, for excellent technical assistance.
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FIG E1. Protein array signal intensities for a-IFNs. Heatmap of signal
intensities in 14 patients with IPEX and 24 healthy controls for IFNs present
on the protein array. Samples reactive with a-IFNs are exclusively patients
with IPEX.
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FIG E2. Competition assays for USH1C and ANKS4B. USH1C and ANKS4B
autoantibodies were tested for cross-reactivity. Radio-ligand binding
assays were performed in presence of increasing amounts of unlabeled
protein. Radiolabeled antigens (*) were competed against unlabeled pro-
tein. The x-axes denote the ratios of labeled to unlabeled protein. No
competition was observed, suggesting that USH1C and ANKS4B were
independent antigens.
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FIG E3. Verification of novel autoantigens with independent methods in
extended case and control groups. The previously identified autoantigens
harmonin (USH1C) and glutamate decarboxylase-65 (GAD2), and the novel
candidate autoantigens harmonin-interacting protein (ANKS4B), HNF4A,
RXRA, and PPARG, showed elevated signals in the protein array screening
(A), and were validated using radio-ligand binding assays (B). All 14 pa-
tients with IPEX from the discovery screen and 3 new patients with IPEX
were assessed. Additional control subjects were included: 75 healthy blood
donors; 20 subjects with APS1; 40 subjects with APS2 (10 with and 10
without type 1 diabetes mellitus); and 20 subjects with inflammatory bowel
disease (10 with ulcerative colitis and 10 with Crohn disease).
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FIG E4. Comparison of protein array and RLBA results. Patients with IPEX who had weakly elevated signals
in the protein array screen came out positive in the validation experiments using the sensitive radio-ligand
binding assays. The x-axes display the fluorescence signal intensities detected in the protein array
experiment on a logarithmic scale. The y-axes display autoantibody index from the RLBAs. Each data point
represents a patient with IPEX (n5 14).Dotted linesmark the cutoff levels for the RLBAs.RLBA, Radio-ligand
binding assay.
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FIG E5. Nuclear receptor autoantibodies target a shared epitope in the
ligand-binding domain. A, The RLBA results for PPARG and HNF4A autoan-
tibodies were similar. Results from single patients with IPEX are connected
with lines (n 5 14). B-D, Competition assays were used to study autoanti-
body cross-reactivity. Radiolabeled nuclear receptor autoantigens (*)
were competed against unlabeled protein of the same autoantigen species,
other nuclear receptor autoantigens, and ANKS4B as a negative control.
The x-axes denote ratios of labeled to unlabeled protein. E, The heatmap
displays signal intensities for the nuclear receptors in the protein array or-
dered by sequence similarity. The 4 patients with IPEX with the strongest
signals for nuclear receptor autoantigens are included. The strongest signal
among healthy controls has been summarized in 1 column, to illustrate that
all healthy controls had weak signals for all nuclear receptors. RLBA, Radio-
ligand binding assay.
=
J ALLERGY CLIN IMMUNOL
JULY 2019
330.e6 LETTERS TO THE EDITOR
FIG E6. Autoantibodies are undetectable following allogenic HSCT. A, The autoantibody profiles detected
in consecutive samples from 4 patients with IPEX undergoing immunosuppressive treatment and/or HSCT.
Each subpanel includes data from a single patient. Complete normalization of autoantibody levels was seen
1.5 years and 5 years after HSCT. B, A principle component (PC) space calculated from RLBA results. The
investigated patient and control samples are indicated with dots. Patients sampled before (diamonds)
and after (squares) HSCT moved (connecting lines) away from the scattered cluster of patients with IPEX
(red) to the cluster of healthy controls (black), as autoantibodies became undetectable. RLBA, Radio-
ligand binding assay.
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TABLE E1. Clinical and genetic characteristics of patients with IPEX syndrome
Patient
Age at
sampling Enteropathy T1DM Dermatitis Additional diagnoses FOXP3 mutation




2 28 y Yes, 5 mo No Yes, 5 mo Arthritis; ITP; renal cell
carcinoma; lymphoma
c.81612 T del (splice donor variant)
3 10 y Gastritis, 8 y No No Low-molecular-weight proteinuria c.21011 G>C (splice donor variant)
4 10 y Yes, 4 mo Yes, birth Yes, birth AIHA; thrombocytopenia c. 1040 G>A (p.R347H) (FKH dom)
5 3 y Yes, 1 mo No No None c.750-752del (p.E250del)
6 5 mo Yes, 1 mo Yes, birth No None c.736-1 G>A (splice acceptor site)
7 17 y Yes, 2 mo No No None c.1222 G>A (p.V408M)
8 1 y Yes, 6 mo Yes, 10 d Yes, 3 mo None c.1117 TT>GC (p.F373A) (FKH dom)
9 18 y Yes, 1 mo Yes, 2 y Yes, 1 mo AIHA; alopecia;
autoimmune thyroiditis; arthritis
c.1150 G>A (p.A384T) (FKH dom)
10 6 y Yes, 40 d No Yes, 40 d AIHA; lymphadenopathy;
CMV hepatitis
c.1078 C>T (p.L360F)
11 3 y Yes, 2 y No No None c.1190 G>A (p.R397Q)
12 28 y Yes, 7 mo Yes, 18 y Yes, 18 y Hepatitis c.1040 G>A (p.R347H)
13 1 y Yes, 3 mo Yes, 2 w Yes, 1 mo Autoimmune thyroiditis;
neurodevelopmental
delay; hepatitis
c.21012 T>G (splice donor variant)
14 1 y No Yes, 10 mo No None c.21012 T>G (splice donor variant)
15 27 y Yes, 3 mo Yes Yes None c.1150 G>A (p.A384T) (FKH dom)
16 1 y Yes, 4 mo No Yes, 2 mo None c.81615C>T (splice donor variant)
17 3 y Yes, 2 mo No Yes, 3 mo AIHA c.751-753delGAG (p.Glu251del)
AIHA, Autoimmune hemolytic anemia; CMV, cytomegalovirus; FKH dom, forkhead domain; ITP, immune thrombocytopenic purpura; T1DM, type 1 diabetes mellitus.
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